Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

LUND, SE / ACCESSWIRE / October 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced new results from the CAN10 phase 1 clinical study. All nine groups, including 68 participants receiving a single dose …
Jetzt den vollständigen Artikel lesen